Author contact

MdeJongMonique C. de Jong
Place and date of birth: Leiden, The Netherlands; August 29th, 1982.
Nationality: Dutch.
View LinkedIn profile

Contact information:
Mail: Department of Radiation Oncology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE Amsterdam, The Netherlands.
Phone:  +31 20 512 9111

2006                  Six-week internship Radiation Oncology: Princess Margaret Hospital, Toronto, Canada.
2007                  Doctor of Medicine (MD): Utrecht University, The Netherlands.
2007 – now        Trainee Radiation Oncology (Chair: prof. dr. M. Verheij) and PhD-Student Radiobiology (Supervisor: prof. dr. A.C. Begg): The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (, Amsterdam, The Netherlands.

de Jong MC, Pramana J, Knegjens JL, Balm AJ, van den Brekel MW, Hauptmann M, Begg AC, Rasch CR (2010). HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiotherapy and oncology 95: 365–70.
Available from:

de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, Takes RP, Kaanders JH, van der Laan BF, Wachters J, Jansen JC, Rasch CR, van Velthuysen ML, Grénman R, Hoebers FJ, Schuuring E, van den Brekel MW, Begg AC (2010). CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clinical cancer research 16: 5329–38.
Available from:

Egelmeer AG, Velazquez ER, de Jong JM, Oberije C, Geussens Y, Nuyts S, Kremer B, Rietveld D, Leemans CR, de Jong MC, Rasch C, Hoebers F, Homer J, Slevin N, West C, Lambin P (2011). Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiotherapy and oncology 100: 108–15.
Available from: